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The hypomyelinating leukodystrophies X-linked Pelizaeus-Merzbacher disease (PMD) and Pelizaeus-Merzbacher–
like disease (PMLD) are characterized by nystagmus, progressive spasticity, and ataxia. In a consanguineous family
with PMLD, we performed a genomewide linkage scan using the GeneChip Mapping EA 10K Array (Affymetrix)
and detected a single gene locus on chromosome 1q41-q42. This region harbors the GJA12 gene, which encodes
gap junction protein a12 (or connexin 46.6). Gap junction proteins assemble into intercellular channels through
which signaling ions and small molecules are exchanged. GJA12 is highly expressed in oligodendrocytes, and,
therefore, it serves as an excellent candidate for hypomyelination in PMLD. In three of six families with PMLD,
we detected ﬁve different GJA12 mutations, including missense, nonsense, and frameshift mutations. We thereby
conﬁrm previous assumptions that PMLD is genetically heterogeneous. Although the murine Gja12 ortholog is not
expressed in sciatic nerve, we did detect GJA12 transcripts in human sciatic and sural nerve tissue by reverse-
transcriptase polymerase chain reaction. These results are in accordance with the electrophysiological ﬁnding of
reduced motor and sensory nerve conduction velocities in patients with PMLD, which argues for a demyelinating
neuropathy. In this study, we demonstrate that GJA12 plays a key role in central myelination and is involved in
peripheral myelination in humans.
Introduction
The hypomyelinating X-linked leukodystrophy Peli-
zaeus-Merzbacher disease (PMD [MIM #312080]) (ﬁg.
1) is characterized by nystagmus, impaired motor de-
velopment, ataxia, choreoathetotic movements, dysar-
thria, and progressive spasticity. The disease is caused
by mutations in the PLP1 gene, which encodes proteo-
lipid protein 1. PLP1 is the major component of myelin
in the CNS and is also expressed in myelin of the pe-
ripheral nervous system (for review, see Koeppen and
Robitaille [2002] and Hudson [2003]). Patients with the
PMD phenotype but without mutations or duplications
of the PLP1 gene are considered to have Pelizaeus-Merz-
bacher–like disease (PMLD [MIM 311601]). No gene
locus has been described for this disease entity.
Gap junction proteins are members of a large family
of homologous connexins and comprise four transmem-
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brane, two extracellular, and three cytoplasmic domains
(ﬁg. 2) (Willecke et al. 2002; Nagy and Rash 2003;
Nagy et al. 2003). They have been identiﬁed in a broad
range of mammalian tissues, and most tissues express
more than one species of connexin protein. The for-
mation of homo- or heteromeric hemichannels (or con-
nexons) by six connexins permits a high level of diver-
sity in channel composition. Two connexons span the
plasma membrane of closely apposed cells and align to
intercellular channels, thus allowing for the exchange
of small molecules, including second messengers and
ions. Gap junctional intercellular communication fulﬁls
multiple functions to meet the speciﬁc needs of tissues.
Several neurological diseases, such as oculodentodigital
dysplasia (Paznekas et al. 2003) and heterogeneous sen-
sorineural deafness (Rouan et al. 2001), are associated
with mutations of genes that encode single members of
the gap junction protein family.
For efﬁcient conduction, axons are surrounded by
multilamellar myelin membranes that are synthesized
by oligodendrocytes and Schwann cells (for review, see
Garbern et al. [1997]). Gap junction protein b1 (GJB1,
or connexin 32) is crucial for peripheral myelination,
and GJB1 mutations lead to X-linked demyelinating
peripheral neuropathy Charcot-Marie-Tooth type 1
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Figure 1 Axial T2-weighted magnetic resonance images of the brain at the level of the basal ganglia. A, Patient with PMLD at 6 years
of age (patient III:3; ﬁg. 3). B, Patient with PMD at 7 years of age. The patients in panels A and B show nearly identical hypomyelination
patterns of central white matter, as indicated by diffusely enhanced signal intensity. C, Low signal of normal myelination in an unaffected child.
(CMTX1 [MIM #302800]) (Bergoffen et al. 1993). Sim-
ilar to PLP1, GJB1 is expressed in both the peripheral
and the central nervous system. In consequence, it is
not surprising that patients with CMTX1 and speciﬁc
GJB1 mutations have both peripheral neuropathy and
a mild or transient brain disorder (Paulson et al. 2002;
Hanemann et al. 2003; Takashima et al. 2003). Vice
versa, a few patients with PMD who have speciﬁc PLP1
mutations have demyelinating peripheral neuropathy in
addition to their hypomyelinating leukodystrophy (Gar-
bern et al. 1997). Here, we report that mutations of the
gap junction protein a12 gene (GJA12, or connexin
46.6) are associated with one type of PMLD and that
this type is also accompanied by a mild peripheral
neuropathy.
Patients and Methods
Families with PMLD and Collection of DNA
We collected blood samples from patients and family
members after obtaining written informed consent, and
we isolated DNA from peripheral blood lymphocytes
according to standard procedures. The study was ap-
proved by the Ethics Review Board at the Charite´ in
Berlin and collaborating institutions, according to the
Declaration of Helsinki. We studied a total of nine pa-
tients and 20 relatives from six unrelated families. The
diagnosis of PMLD was made on the basis of clinical
criteria and magnetic-resonance-imaging ﬁndings (Cail-
loux et al. 2000; Schiffmann and Boespﬂug-Tanguy
2001; Koeppen and Robitaille 2002; Hudson 2003;
Plecko et al. 2003). The sensory- and motor-nerve con-
duction velocities (SCVs and MCVs, respectively) were
investigated in patients (table 1) and in heterozygous
family members II:2, II:3, and III:2 of family 1 (ﬁg. 3).
In all patients with PMLD, PMD was ruled out by mu-
tational analysis of the PLP1 coding region, the ﬂanking
intron sequences, and its promoters. Duplications of
PLP1 were ruled out by Southern blot or real-time PCR.
In addition, we found different haplotypes at the PLP1
gene locus in the two affected brothers (III:1 and III:3;
ﬁg. 3) of index family 1 (data not shown). This ﬁnding
excludes a causative role of PLP1 in this family.
Genome Scan and Haplotype Analysis
For the whole-genome scan, we used the GeneChip
Mapping EA 10K Array (Affymetrix) according to the
guidelines of the manufacturer. This early-access ver-
sion of the Mapping 10K comprised a total of 10,043
SNPs. The mean intermarker distance was 250 kb,
equivalent to 0.34 cM. Individuals I:1–I:4, II:1–II:4,
and III:1–III:8 of family 1 were genotyped (ﬁg. 3). The
following 12 informative SNP markers were used for
haplotype reconstruction and analysis: rs958413,
rs3902857, rs725033, rs1563353, rs1389742,
rs2378627, rs1369847, rs1343743, rs544528, rs559272,
rs1321257, and rs1933633 (dbSNP Home Page).
PedCheck was used for detection of Mendelian errors
(O’Connell and Weeks 1998). Non-Mendelian errors
were identiﬁed by MERLIN (Abecasis et al. 2002).
Parametric linkage and haplotype analysis were per-
formed by a modiﬁed version of GENEHUNTER
(Strauch et al. 2000), through use of a sliding window
with sets of 50 SNPs. All physical positions are derived
from National Center for Biotechnology Information
build 34, July 2003.
Sequence Analysis
We designed a set of three primer pairs to amplify the
single exon of GJA12 (GenBank accession number
NM_020435) and its ﬂanking sequences from genomic
DNA (GenBank accession number NT_004559): 1F (5′
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Figure 2 Domains of the GJA12 gene product. Blackened circles depict the locations of mutations. The missense mutations lie within the
second (P90S) and fourth (Y272D) transmembrane and third cytoplasmic (M286T) domains.
TTT AAG GCG GTA AGC TCC AC 3′) and 1R (5′ CAG
CAT GGG CTC CTC CTC 3′), 2F (5′ CTG CGA CAA
CGT CTG CTA TG 3′) and 2R (5′ GCC ATC TCA CAG
AGG TTG AG 3′), and 3F (5′ CCG ACC GGG CAA
CAC GAT G 3′) and 3R (5′ GAG TCT GCC TGA GGC
CAC CG 3′). For GC-rich fragments, 1 M betaine was
used as an additive. For ampliﬁcation of the coding
region of GJB1 (GenBank accession number NM_
000166) and its ﬂanking sequences from genomic DNA
(GenBank accession number NT_011669), we used the
following oligonucleotides: 4F (5′ TGA CCA TCC TTC
CTT TCC TG 3′), 4R (5′ ACA TGA AGA CGG CCT
CAA AC 3′), 5F (5′ GGC TCA CCA GCA ACA CAT
AG 3′), and 5R (5′ AGT AGC CAG GGA AGG AAG
GT 5′).
PCR products were directly sequenced using an ABI
PRISM 3730 DNA Analyzer and BigDye Terminator
Cycle Sequencing Kit version 1.1, according to the pro-
tocol of the manufacturer (Applied Biosystems).
We veriﬁed the intrafamilial segregation of all muta-
tions by RFLP analysis (ﬁg. 4). We used primer-induced
restriction analysis for all mutations without natural re-
striction sites (the size [in bp] of the fragments yielded
after restriction with each endonuclease is given; prim-
er mismatches are underlined): c.268CrT: primers 2F
and 1R, HpyCh4IV, mutantp 9  33  38  179 bp,
wild type p 9  33  217 bp; c.718CrT: primers 3F
and 3R, MaeIII, mutant p 716  137 bp, wild typep
853 bp; c.814TrG: primers 3F and 3R, RsaI, mutantp
9  57  58  729 bp, wild type p 9  57  58 
111 618 bp; c.857TrC: primers 6F (5′ GTACCTGCT
GTA CGG CTT CG 3′) and 6R (5′ GCT GCC CAA GCC
CAG GTC GGC C 3′), EagI, mutant p 166  21 bp,
wild typep 187 bp; and c.989delC: primers 3F and 7R
(5′ CGC ACC ACC AGG CTG TAG TCG GCC G 3′),
SﬁI, mutant p 108  326 bp, wild type p 25  83 
326 bp. Primer sequences of TGFB2, MARK1, CAPN2,
DEGS, ENAH, and IMAGE3451454 are available from
the authors on request.
RT-PCR
Total RNA was extracted from fresh frozen sural and
sciatic nerve specimens from adult healthy individuals
by the TRIzol reagent (Invitrogen). RNA from adult
brain, spinal cord, and skeletal muscle was purchased
from CLONTECH. Integrity of RNA was veriﬁed on an
agarose gel by visualization of the 5S, 18S, and 28S
rRNA bands. Two micrograms of total RNA were sub-
jected to reverse transcription by use of the RevertAid
First Strand cDNA Synthesis Kit (Fermentas). Equal
loading of template was veriﬁed by simultaneous am-
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Figure 3 Haplotypes in family 1 with PMLD. Haplotype analy-
sis indicated that the cosegregating segment of the PMLD locus is
ﬂanked proximally by marker rs3902857 and distally by marker
rs1321257 on chromosome 1q41-q42.
pliﬁcation of ACTB as an internal standard. GJA12 was
ampliﬁed by primers 2F and 2R; for GJB1, we used
primers 8F (5′ ACT CCC CCT GCA CAG ACA T 3′)
and 8R (5′ TCT CAT CAC CCC ACA CAC TC 3′). To
exclude the provenience of the PCR bands from genomic
DNA, we performed control-PCR runs with the above
mentioned primers on RT-reaction products in which
reverse transcriptase had been omitted. None of the re-
actions yielded a band. For a relative estimate of the
amounts of cDNA, we interrupted ampliﬁcation of
GJA12 and GJB1 after 28, 34, and 40 cycles.
Protein Alignment
We performed multiple alignments (ﬁg. 5) (Gja12_
fugu [GenBank accession number CAAB01002259.1],
GJA12_human [GenBank accession number NP_
065168], Gja12_mouse [UniProt TrEMBL accession
number Q9EPM1], and Gja12_rat [UniProt TrEMBL
accession number Q80XF7]) with the CLUSTAL W pro-
gram, version 1.74 (Thompson et al. 1994).
Results
Phenotypic Features
All patients with PMLD with GJA12 mutations (fam-
ilies 1, 2, and 3) showed the characteristic clinical symp-
toms of the hypomyelinating leukodystrophies PMDand
PMLD (ﬁg. 1), such as nystagmus, impaired motor de-
velopment, ataxia, choreoathetotic movements, dysar-
thria, and progressive spasticity (Nezu et al. 1996; Laz-
zarini et al. 1997; Cailloux et al. 2000; Schiffmann and
Boespﬂug-Tanguy 2001; Koeppen and Robitaille 2002;
Hudson 2003; Plecko et al. 2003). Nystagmus and poor
head and trunk control were the presenting symptoms
in early infancy (table 1). By the age of 8–15 mo, an
impaired motor development became apparent when de-
velopmental milestones like unaided sitting and/or walk-
ing were delayed or could not be achieved. Only one
patient was able to walk a few steps at the age of 5
years. All patients experienced facial weakness. In ad-
dition, the patients in families 1 and 2 had focal epileptic
seizures prior to adolescence (table 1). In addition to the
involvement of the CNS, PMLD associated with GJA12
mutations seems to be accompanied by a mild peripheral
neuropathy. MCVs and SCVs of the lower limb nerves
were reduced or slightly below the age-corrected normal
values in most patients (table 1). Nerve conduction ve-
locities of the median nerve, available only in members
of family 1, were reduced only in patient III:3. Hetero-
zygous individuals had no neurologic symptoms. In con-
trast to the cranial magnetic resonance imaging (cMRI)
of all patients, the cMRIs of two heterozygous healthy
members of family 1 (II:2 and II:3; ﬁg. 3) did not reveal
any abnormality (data not shown).
The phenotype of the patients with PMLD without
GJA12 mutations was not clearly different from that of
patients with GJA12 mutations. However, two of four
patients without GJA12 mutations did not present with
nystagmus in infancy.
PMLD Locus on Chromosome 1q41-q42
Genomewide linkage scanning revealed linkage of
PMLD to SNPs on chromosome 1q41-q42. Multipoint
linkage analysis yielded a maximum LOD score of 4.83
for SNP markers rs1563353–rs544528. No additional
peak with a LOD score value 11 was found in the
genome (ﬁg. A1 of the appendix [online only]). Hap-
lotype analysis disclosed recombination events in in-
dividual III:4 of family 1 that conﬁned the candidate
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Figure 4 Segregation of GJA12 mutations (RFLP analysis). In family 2 (f2), the affected boy was compound heterozygous, carrying the
paternal c.268CrT missense mutation and the maternal c.989delC frameshift deletion. In family 3 (f3), the affected boy carried the paternal
c.718CrT nonsense mutation and the maternal c.814TrG missense mutation. Family numbers correspond to those in table 1. co p control;
f1–f3 p families 1–3; mut p mutated GJA12; wt p wild-type GJA12.
locus to a region distal to SNP rs3902857 (physical
map position 215.5 Mb) and proximal to SNP
rs1321257 (physical map position 227.3 Mb) (ﬁg. 3).
Consistent with parental consanguinity, the affected
siblings III:1 and III:3 and the affected cousin III:4 were
autozygous for all SNPs within the cosegregating seg-
ment. The expression of Gja12 in murine oligoden-
drocytes (Menichella et al. 2003; Odermatt et al. 2003)
led to the singling out of GJA12 (physical map position
225.3 Mb) as one of the most promising candidate
genes. Mutations in the coding region and its ﬂank-
ing intronic sequences of TGFB2, MARK1, CAPN2,
DEGS, ENAH, and IMAGE3451454 were ruled out
by sequence analysis.
PMLD Gene GJA12
GJA12 is composed of a single exon.We analyzedDNA
samples from six families with PMLD. In one Turkish
consanguineous (family 1; ﬁg. 3) and two German non-
consanguineous families, we identiﬁed ﬁve different
GJA12 mutations (ﬁg. 2 and table 1). We could not ﬁnd
GJA12 mutations in three other affected families. As ex-
pected, patients from the consanguineous family dis-
played a homozygous mutation, and patients from the
nonconsanguineous families were compound heterozy-
gous for theGJA12mutations. A homozygous c.857TrC
transition predicts a substitution of threonine for methi-
onine in family 1 (M286T). A heterozygous c.268CrT
transition (paternal allele) predicts a substitution of serine
for proline (P90S), and a heterozygous c.989delC 1-bp
deletion (maternal allele) leads to a frameshift and a non-
sense peptide of 141 amino acids after amino acid 329
(cysteine) in family 2. A heterozygous c.718CrT transi-
tion (paternal allele) represents a nonsense mutation
(R240X), and a heterozygous c.814TrG transversion
(maternal allele) leads to the replacement of tyrosine by
aspartic acid (Y272D) in family 3.
Several ﬁndings supported the hypothesis that muta-
tions in GJA12 are the primary cause for a subgroup of
PMLD and are consistent with an autosomal recessive
mode of inheritance: (i) no missense mutations were de-
tected in 220 alleles of 110 unaffected individuals, which
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Figure 5 Alignment of selected regions of human GJA12 with
orthologs of other species, including the Japanese pufferﬁsh Fugu rub-
ripes. Arrows indicate positions of the missense and nonsense muta-
tions in patients with PMLD. Family numbers correspond to those in
table 1. f1–f3 p families 1–3.
Figure 6 PCR products of GJA12 andGJB1 cDNA after various
numbers of PCR cycles in human brain, spinal cord, sciatic and sural
nerve, and skeletal muscle. GJA12 and GJB1 are more highly ex-
pressed in brain and spinal cord than in peripheral nerve tissue. Un-
transcribed RNA was used as a control (co).
rules out common polymorphisms; (ii)GJA12mutations
segregated with the disease phenotype in all families (ﬁg.
4); and (iii) all residues affected by the three missense
mutations are highly conserved (ﬁg. 5).
A silent c.594CrT GJA12 polymorphism was found
in families 3 and 6 and in 3 of 20 healthy individuals.
Furthermore, since Gja12 and Gjb1 reveal a high level
of functional redundancy in murine oligodendrocytes
(Menichella et al. 2003; Odermatt et al. 2003), we an-
alyzed not only GJA12 but also GJB1. We did not ﬁnd
mutations in the coding region of GJB1 or in its ﬂanking
intronic sequences in any of the six families with PMLD.
Expression of GJA12 in the Central and Peripheral
Nervous System
To further investigate the reduced MCVs in two pa-
tients with PMLD (table 1), we examined the GJA12
expression in comparison with that of GJB1 by RT-PCR
analysis in human sciatic and sural nerve specimens.
GJA12 cDNA could be ampliﬁed from sciatic and sural
nerves of healthy adults (ﬁg. 6). Intensities of PCR prod-
ucts were compared after various numbers of PCR cy-
cles, to estimate relative amounts of GJA12 and GJB1
transcripts. Although GJA12 and GJB1 bands both ap-
peared after 28 cycles in brain and spinal cord, they were
not detectable in sciatic and sural nerve before 34 cycles
or in skeletal muscle before 40 cycles (ﬁg. 6). Thus, the
highestGJA12 andGJB1 transcript numberswere found
in brain and spinal cord, and the lowest were found in
skeletal muscle.
Discussion
In this study, we demonstrate that mutations of the
GJA12 gene are associated with one form of autosomal
recessive PMLD. In three of six affected families with a
similar phenotype, we could not ﬁnd GJA12 mutations,
a ﬁnding that complies with previous reports that PMLD
is a group of genetically heterogeneous diseases (Laz-
zarini et al. 1997; Schiffmann and Boespﬂug-Tanguy
2001). In addition to the characteristic clinical symp-
toms, patients with PMLD with GJA12 mutations had
peripheral neuropathy and seizures, both of which occur
only sporadically in PMD (Garbern et al. 1997; Cailloux
et al. 2000; Koeppen and Robitaille 2002).
Some patients showed reduced nerve conduction ve-
locities, which indicate the presence of a mild peripheral
demyelinating motor neuropathy, predominantly of the
lower limbs. This complies with our ﬁnding that GJA12
is expressed not only in the CNS but also in sural and
sciatic nerve tissue. However, in the murine sciatic
nerve, Gja12 was not found to be expressed, as dem-
onstrated by the absence of ﬂuorescence from theEGFP
reporter gene, which replaced the Gja12 coding DNA
(Odermatt et al. 2003), as well as by northern blot
analysis of the sciatic nerve in wild-type mice (Teubner
et al. 2001). Ampliﬁcation of small amounts of GJA12
and GJB1 from human skeletal muscle RNA might be
explained by ampliﬁcation frommuscle tissue itself or—
more likely—from small amounts of nerve ﬁbers within
skeletal muscle. Furthermore, seizures were a frequent
ﬁnding in our subgroup of patients with PMLD. This
observation supports the hypothesis of Samoilova et al.
(2003) that gap junctional communication plays an im-
portant role in the incidence of seizures. The ﬁnding
thatGJA12mutations are associated with one subgroup
of PMLD provokes questions concerning those cellular
mechanisms that lead to the phenotype of hypomyeli-
nating leukodystrophy. Our data and the studies of
other groups suggest mechanisms other than merely a
loss of GJA12 function.
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Gja12-knockout mice are completely Gja12-deﬁ-
cient but clinically normal (Odermatt et al. 2003). In
contrast, our patients are affected by missense muta-
tions on one or both alleles and therefore should syn-
thesize mutant GJA12 protein. It has been shown that
mutant gap junction proteins may become toxic. For
instance, the GJB1 mutant S85C forms functional cell-
cell channels, and its hemichannels show an increased
opening (Abrams et al. 2002). The GJA12 missense
mutation P90S of family 2 (table 1) is located close to
the CMTX1-associated S85C missense mutation of the
paralogous GJB1. If, in fact, GJA12 mutant proteins
became toxic in PMLD, a gain of toxic function might
depend on mutant gene dosage, since all heterozygous
members of families 1–3 were healthy.
In coexpression studies, it has been shown that mu-
tant gap junction proteins can inhibit functions of other
wild-type connexins. Most cell types express more than
one gap junction protein species and form gap junctions
by single or different protein species (Rouan et al. 2001).
Similar to Gja12 and Gjb1 in murine oligodendrocytes
(Menichella et al. 2003), GJB2 (or connexin 26) and
GJA1 (or connexin 43) colocalize in human hyperker-
atotic skin (Rouan et al. 2001). In coexpression studies
in Xenopus oocytes, GJB2 mutants partially blocked the
function of wild-type GJA1. Similar negative effects
have been shown by Gja1 mutants on wild-type Gjb1
(Lagree et al. 2003). The use of site-directed mutagen-
esis of GJA12 and GJB1 for cotransfection in cellular
systems will help to clarify the pathogenicity of each
connexin mutant.
Both Gjb1 and Gja12 are functionally redundant in
murine oligodendrocytes (Menichella et al. 2003; Od-
ermatt et al. 2003). Although Gja12 or Gjb1 null mu-
tants show no clinical abnormalities, mice lacking both
Gja12 and Gjb1 develop severe oligodendrocyte death
and present with tremor and tonic seizures (Scherer et
al. 1998; Menichella et al. 2003; Odermatt et al. 2003).
For this reason, we carefully ruled out mutations in the
coding region ofGJB1 in all families with PMLD. Under
the hypothesis that GJB1 can compensate for the loss
of GJA12 not only in mice (Menichella et al. 2003;
Odermatt et al. 2003) but also in humans, mechanisms
other than loss of GJA12 function should be proposed
for our patients with PMLD.
GJB1 mutations lead to demyelinating peripheral
neuropathy CMTX1 (Bergoffen et al. 1993; Lin et al.
1999; Hahn et al. 2000). Patients with CMTX1 and
speciﬁc GJB1 mutations also present with CNS symp-
toms (Paulson et al. 2002; Hanemann et al. 2003; Taka-
shima et al. 2003) similar to those seen in PMLD. This
is in contrast to patients with deletions of the entire
GJB1 coding sequence who are not affected by brain
disorders (Kleopa et al. 2002; Hanemann et al. 2003).
These data suggest that other gap junction proteins may
compensate for a loss of central GJB1 function and that
distinct GJB1 mutants may have negative effects on oli-
godendrocytes in humans. We assume that the patho-
mechanisms in GJA12-related PMLD are similar.
GJA12 seems to be more important for oligodendro-
cyte homeostasis than GJB1. In fact, the central symp-
toms in CMTX1 (Paulson et al. 2002; Hanemann et al.
2003; Takashima et al. 2003) are transient or milder
than in PMLD, and, in contrast to Gja12-knockout an-
imals, which show subtle ultrastructural myelin abnor-
malities in the optic nerve system (Odermatt et al.
2003), Gjb1-knockout mice do not display pathological
changes of myelination in optic nerves (Scherer et al.
1998).
In summary, mutations of GJA12 are associated with
one form of autosomal recessive PMLD. Since Gjb1 and
Gja12 are functionally redundant in mice, we favor the
hypothesis that the missense mutants found in our pa-
tients with PMLD display toxic gain of function in oli-
godendrocytes, as speciﬁc GJB1 mutants may do with
regard to central functions of GJA12 in CMTX1.
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